Heidelberg Pharma AG
General information
Heidelberg Pharma AG
Gregor-Mendel-Straße 22
68526 Ladenburg, Baden-Württemberg
Germany
Contact person: Jan Schmidt-Brand, Chief Executive Officer
Company main phone: +49 (6203) 10090
Company main fax: +49 (6203) 100919
Website: https://www.heidelberg-pharma.com
Gregor-Mendel-Straße 22
68526 Ladenburg, Baden-Württemberg
Germany
Contact person: Jan Schmidt-Brand, Chief Executive Officer
Company main phone: +49 (6203) 10090
Company main fax: +49 (6203) 100919
Website: https://www.heidelberg-pharma.com
| Year founded: | 1997 |
| Source of foundation: | Independent foundation |
| No. of employees: |
Worldwide: 95 |
| No. of R&D employees: | Worldwide: 62 |
Corporate description / mission:
Heidelberg Pharma AG is a biopharmaceutical company working in the field of oncology. The company is focused on the development of Antibody Drug Conjugates (ADCs) for the treatment of oncological diseases. Heidelberg Pharma's so-called ATACs are ADCs based on the ATAC technology that uses Amanitin as an active ingredient. The biological mechanism of action of the Amanitin toxin represents a new therapeutic principle. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Further preclinical development candidates are HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer.
Heidelberg Pharma AG is a biopharmaceutical company working in the field of oncology. The company is focused on the development of Antibody Drug Conjugates (ADCs) for the treatment of oncological diseases. Heidelberg Pharma's so-called ATACs are ADCs based on the ATAC technology that uses Amanitin as an active ingredient. The biological mechanism of action of the Amanitin toxin represents a new therapeutic principle. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Further preclinical development candidates are HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2006
Headquarters: HQ: Yes
IPO (year): 2006
Remarks on ownership / listings
formerly WILEX AG
formerly WILEX AG
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 7 | |
| Phase I: | 3 | |
| Phase II: | 3 | |
| Phase III: | 1 |
Description of products:
HDP-101 - BCMA ATAC
HDP-102 - CD37 ATAC
HDP-103 - PSMA ATAC
HDP-104 - GCC ATAC
HDP-101 - BCMA ATAC
HDP-102 - CD37 ATAC
HDP-103 - PSMA ATAC
HDP-104 - GCC ATAC
Technology used:
ADC technology
ATAC technology
ADC technology
ATAC technology
Financing details
Fiscal year (end of) 2023
| Revenues: | USD 10.49M | |
| R&D expenses: | USD 29.87M | |
| Cash: | USD 46.21M |
| Total liabilities: | USD 22.36M | |
| No. of shares: | 46'605'000 | |
| Market cap. / valuation: | USD 151.61M |
Collaborations & Clients
Partnering strategy / collaborations:
e.g. Takeda Pharmaceutical Company Limited, Chiome Bioscience, Binghamton University (State University of New York)
e.g. Takeda Pharmaceutical Company Limited, Chiome Bioscience, Binghamton University (State University of New York)
© 2024 Biotechgate by Venture Valuation